Search

2 result(s) for 'author#Michael Tillinger' within BMC

1. Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hocanalysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial

   Trauma is a leading cause of mortality and morbidity, with traumatic brain injury (TBI) and uncontrolled hemorrhage responsible for the majority of these deaths. Recombinant activated factor VIIa (rFVIIa) is b...

   Authors: Yoram Kluger, Bruno Riou, Rolf Rossaint, Sandro B Rizoli, Kenneth David Boffard, Philip Iau Tsau Choong, Brian Warren and Michael Tillinger

   Citation: Critical Care 2007 11:R85

   Content type: Research Published on: 8 August 2007

   • View Full Text
   • View PDF

2. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

   We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for ...

   Authors: Sandro B Rizoli, Kenneth D Boffard, Bruno Riou, Brian Warren, Philip Iau, Yoram Kluger, Rolf Rossaint and Michael Tillinger

   Citation: Critical Care 2006 10:R178

   Content type: Research Published on: 21 December 2006

   • View Full Text
   • View PDF